

Ref: FOI/GS/ID 7559

**Please reply to:**  
FOI Administrator  
Trust Management  
Maidstone Hospital  
Hermitage Lane  
Maidstone, Kent  
ME16 9QQ  
Email: [mtw-tr.foiadmin@nhs.net](mailto:mtw-tr.foiadmin@nhs.net)  
[www.mtw.nhs.uk](http://www.mtw.nhs.uk)

27 July 2022

## **Freedom of Information Act 2000**

I am writing in response to your request for information made under the Freedom of Information Act 2000 in relation to Diffuse Large B Cell Lymphoma (DLBCL).

*You asked:*

- Q1. Does your trust treat patients with Diffuse Large B Cell Lymphoma (DLBCL)? If not, then which trust do you refer DLBCL patients to?*
- Q2. In the last 6 months, how many patients have you treated for Diffuse Large B Cell Lymphoma (DLBCL)?*
- Q3. In the last 6 months, how many patients have you treated for Diffuse Large B Cell Lymphoma (DLBCL) with the following treatments:*
- a. R-CHOP (rituximab, cyclophosphamide, doxorubicin hydrochloride, vincristine and prednisolone)*
  - b. R-mini-CHOP (rituximab, cyclophosphamide, doxorubicin hydrochloride, vincristine and prednisolone)*
  - c. Other immuno-chemotherapy*
  - d. Other chemotherapy*
  - e. Stem cell transplant or bone marrow transplant (autologous or allogeneic)*
  - f. Pola-BR (polatuzumab vedotin with rituximab and bendamustine) - any line of treatment*
  - g. Pola-BR (polatuzumab vedotin with rituximab and bendamustine) - third-line treatment only*
  - h. Tisagenlecleucel*
  - i. Axicabtagene ciloleucel*
  - j. Lisocabtagene maraleucel*
- Q4. In the last 6 months, how many Diffuse Large B Cell Lymphoma (DLBCL) patients have you referred to other trusts for:*
- a. Stem cell transplant or bone marrow transplant (autologous or allogeneic)*
  - b. CAR-T therapy (Tisagenlecleucel, Axicabtagene ciloleucel, Lisocabtagene maraleucel)*

Q5. Do you participate in any active clinical trials for Diffuse Large B-Cell Lymphoma (DLBCL)? If so, can you please provide the name of each trial along with the number of patients taking part?

Trust response:

Q1. Yes

Q2. 58

Q3.

a. 35

b. 5

c. Please see notes below

d. Please see notes below

e. Not on our system

f. 2

g. We are unable to identify the line of treatment for the above two patients

h. Not on our system

i. Not on our system

j. Not on our system

Please note: The Trust has another 19 patients with the treatment appointment listed below where we are unable to allocate them to Other immuno-chemotherapy or other chemotherapy accurately.

GEMCITABINE, OXALIPLATIN & RITUXIMAB 3

IBRUTINIB 1

IMMUNOGLOBULIN INFUSION 2

INTRATHECAL CHEMOTHERAPY 1

KIOVIG 1

Off Protocol RGDP 3

PRIVIGEN IV 1

R-CEOP 3

R-DA-EPOCH 1

R-GCVP 1

RITUXIMAB (Haem) 2

Q4.

Q5. REMoDL-A (A Randomised Phase II Evaluation of Molecular Guided Therapy for Diffuse Large B-Cell Lymphoma with Acalabrutinib) - IRAS 266600

4 patients have been recruited and it is still open to recruitment